GRANULES INDIA
-
Paracetamol maker Granules India's profit drops as lower prices in US, Europe pinch
Granules, which generates about two-thirds of its revenue from North America and 19 per cent from Europe, posted a 2 per cent rise in its revenue from operations.
-
USFDA pulls up Granules India for lapses in maintaining storage facilities, equipment at Telangana plant
-
USFDA issues warning letter for Granules India Gagillapur plant, new product approvals to take a hit
-
Granules India gets USFDA nod for generic drug
-
Granules India’s Unit V facility secures US FDA EIR with No Action Indicated status
-
Granules India gets USFDA nod for generic medication to treat depression
-
Granules India receives US FDA's ANDA approval for Trazodone Hydrochloride Tablets USP, 50 mg, 100 mg, 150 mg, 300 mg
Advertisement
Advertisement
Get updates on your preferred social platform
Follow us for the latest news, insider access to events and more.
